TherapeuticsMD (TXMD) Provides Update on Third Quarter Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
TherapeuticsMD Provides Update on Third Quarter Progress
September 25, 2020 9:02 AM EDT-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA®-
-Underlying retail and wholesale demand for ANNOVERA is strong and growing-
-Company experiencing record retail and wholesale growth for ANNOVERA-
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative womens healthcare company, today announced that the Company is on track to meet or exceed third quarter 2020 total net revenue consensus of $15.1 million. For the Companys ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) product, the Company has seen... More
